CANTON, Mich. (March 14, 2024) - TrialAssure, a leading pharmaceutical technology provider advancing clinical trial disclosure, data sharing, and transparency, announced that its flagship product TrialAssure ANONYMIZE® 3.0 is now available. ANONYMIZE allows users across the pharmaceutical ...
Read MoreTAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC). When evaluated against comparative TROP2 ADCs, OBI-992 demonstrated greater antitumor efficacy, ...
Read MoreSUNNYVALE, Calif. , March 18, 2024 /PRNewswire/ -- Aquedeon Medical, Inc., a Silicon Valley pioneering medical device company specializing in novel cardiothoracic solutions, is pleased to announce a significant milestone with initiation of its investigational device exemption (IDE) clinical ...
Read MoreSHENZHEN, China , March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial (CGZ203 study) of chiglitazar monotherapy for ...
Read MoreSubscribe to our Free Newsletters!